1. Tour de Table Mid-term Meeting 3rd June 2015

2. QEHB Queen Elizabeth Hospital Birmingham, UK Large Teaching Hospital
>1200 beds
Dialysis population >1000
With 800+ patients on HD
400 VA procedures (surgical)
500+ IR procedures

3. QEHB Research interests: ReDVA ESR Vascular access MER
All aspects of renal diseases
Basic science
Renal research
Trials (>20 ongoing)
Vascular access
Completed CTiMP on GTN in AVFs
200 patients recruited
Multiple other trials in process
ReDVA
ESR
Zaib Khawaja
Julien Alshakarchi
MER
Nick Inston
Predominately WP2/3 with Guerbet, Paris

4. Guerbet Group Organization
Marie-Claire Janailhac-Fritsch, Chairman of the Board of Directors
Yves L’Epine, Chief Executive Officer
Marie-Claire Taine,
VP Commercial
Jean-Sébastien Raynaud
Pierre Desché,
VP Development, Medical & Regulatory Affairs
Eric Lancelot

5. Interventional Radiology and Theranostics (IRT)
Guerbet
Four growth drivers
Interventional Radiology and Theranostics (IRT)
X-ray
MRI
Medical Devices (MD)
Xenetix®
Telebrix®
Hexabrix® …
Dotarem®
Artirem® …
Lipiodol®
Patent Blue® …
FlowSens®
Manyfill®
Secufill® … 1 2 3 4

6. Guerbet Principle stages of development
1901: Marcel Guerbet discovered the first iodinated
contrast medium, Lipiodol
1926: André Guerbet founded Laboratoires Guerbet
1989: Dotarem launch for MRI imaging
1995: Xenetix launch for X-ray imaging
2006: ScanBag by Xenetix launch with its bag injector
(SBI by Medex)
2010: Launch of the Fill range of medical devices by Medex
2011: Yves L’Epine appointed CEO
2013: Dotarem launch in the US
2014: Launch of FlowSens, new generation injection
solution in CT imaging

7. Michael Walsh PhD ULIM PI WP5 Leader

8. Team
2014/2015/2016
Michael Walsh PhD – ULIM PI – WP5 Leader - MER Secondee
David Newport PhD – MER Secondee
2014/2015
Stephen Broderick PhD – ER Secondee
Leonard Browne PhD – ESR Secondee
2015/2016
Sinead Morley BE – ESR Secondee
Connor Cunnane BE – ESR Secondee
Recruitment 2015/2016
ER – Numerical Modelling of AV access hemodynamics
ER – Experimental Modelling of AV access hemodynamics

9. Vascular Flow Technologies (VFT) has grown from a tiny surgeon led start-up to a young, innovative Medical Devices Company which has developed and patented the innovative Spiral Laminar FlowTM (SLF) design technology. SLFTM technology restores the natural pattern of blood flow in vascular implants, improving the life of the implant, helping to prevent disease progression and improving outcomes for the patient.
Our global platform technology is underpinned by 18 patent families and two recently filed new patents. We continue to build strong clinical evidence of a clear clinical superiority to current standard of care in the first two indications (Peripheral Vascular Grafts and Arteriovenous Access Grafts). Our business is focused on developing further clinical and health economic evidence and developing new products (stents and catheters) using the SLFTM technology platform within a growing $2.5bn market.

10. Cornerstone investors in place, investing £3.5m to-date.
SLFTM observed and patent-protected by three Scottish Clinicians - Professor Peter Stonebridge, Professor Graeme Houston & John Dick.
Company founded as Tayside Flow Technologies, registered in Scotland, then re-named Vascular Flow Technologies.
First product approved with CE mark for Peripheral Vascular Grafts. Arteriovenous Access Grafts followed in June 2010.
Cornerstone investors in place, investing £3.5m to-date.
CEO Bill Allan appointed; strategy developed to prove commercial concept and build new product pipeline.
US distributor model replaced with direct sales model; influential Clinical Advisory Board appointed. 
New products launched in Europe and USA.
Commercial case for SLFTM proven in the US.
Strategic focus on Clinical Evidence Programme (CEP).
Award of Horizon Phase 1 Grant for Peripheral Stent development.

11. The VFT Team ReDVA SECONDEES Angela Paterson: QA & RA Manager
Bill Allan
Craig Dunlop
The VFT Team
Barbara Bunger
Kate Full
Laurence Ryan
Angela Paterson: QA & RA Manager
Ann Verbrugghe: VP Market Development
Caroline Toms: Admin Manager
Rhonda McCrimmon: Assistant Accountant
Martin Low: Office Assistant
ReDVA SECONDEES
Efstratios Kokkalis: University of Dundee
Stephen Broderick: University of Limerick
Leonard Brown: University of Limerick

12. Tour de table: Dundee Clinical Roles: Background ReDVA
Patient Health Informatics
Patient Questionnaire
Basic Science:
Haemodynamics in Clinical research
MRI in ReDVA
Clinical Trial Research:
Ultrasound protocol
MRI Protocol
Trial Delivery

13. Dundee Team
Expertise: Prof Houston, Stonebridge ( Clinical Vascular/Imaging) Prof Hoskins (Collaborator Edinburgh Ultrasound) Dr Gandy (MRI), Dr Ross (Ultrasound) Dr Aristokleous (Recruit Dundee) ESRs: Stratos Kokkalis ( Flow Rig/CFD - secondee to VFT) Deirdre Cassidy (MRI - secondee to Guerbet) Conor MacDonald (Physics – secondee Guerbet 2016)